The combination of SGLT2 and RAAS inhibition may have superior benefits which include reductions in body weight and blood pressure and reducing the risk of renal outcomes such as nephropathy and acute renal failure, but further data based on head‐to‐head comparisons are needed. This evidence concerns the gene SLC5A2 and Nephropathy.